1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Road Ahead Unclear For Polyphor’s Intravenous Murepavadin

 
• By Alexandra Shimmings

The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.

Finish
• Source: Shutterstock

Polyphor Ltd. has decided to close the two Phase III trials of murepavadin iv for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) that were put on a voluntary temporary hold in May, spelling the likely end for the program.

The Phase III trials – PRISM-MDR and PRISM-UDR – were evaluating murepavadin in patients with nosocomial pneumonia but a higher...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.